All sponsors

Evopoint Biosciences Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO20%

Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Evopoint Biosciences Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
XNW28012
NCT06799637
P1/2RecruitingAdvanced Solid Tumors; Pancreatic Carcinoma3502026-12-31
XNW5004 tablets
NCT06702605
P2Not yet recruitingRelapsed/Refractory Peripheral T Cell Lymphoma502027-01
XNW29016
NCT06987500
P1/2RecruitingTumor, Solid1322027-02-14
XNW28012 for injection
NCT07823049
P3RecruitingPancreatic Cancer2262027-05-31
XNW5004
NCT06702995
P1/2RecruitingMetastatic Castrate-Resistant Prostate Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer)3072027-07-13 (+14 mo)
XNW5004 tablets
NCT07545603
P2RecruitingFollicular Lymphoma, Grade 1; Follicular Lymphoma, Grade 2652027-12-31
XNW34017
NCT07327294
P1/2Not yet recruitingAdvanced Solid Tumors1502027-12-31
NCT06776952
NCT06776952
P3RecruitingRelapsed/Refractory Peripheral T Cell Lymphoma1202028-01
XNW5004 combined with CHOP (incremental)
NCT07730515
P1/2RecruitingNon-hodgkin Lymphoma; Peripheral T-cell Lymphoma1762028-09-30
XNW5004 Tablet
NCT07730580
P2Not yet recruitingAdvanced Prostate Cancer2422028-12-31